

Original Research

# Clinical Efficacy and Therapeutic Mechanism of Acupuncture in the Treatment of Adolescent Depression

Jinlan Jiang<sup>1,2</sup> , Baohua Ji<sup>2,3</sup> , Wei Jin<sup>4</sup> , Peiyun Zhang<sup>1</sup> , Haoran Chen<sup>5</sup> ,  
Wenjie Cong<sup>6</sup> , Xiaoqing Jin<sup>7,\*</sup> , Lihong Li<sup>8,\*</sup> 

<sup>1</sup>The Second School of Clinical Medicine, Zhejiang Chinese Medical University, 310053 Hangzhou, Zhejiang, China

<sup>2</sup>Wenzhou Institute, University of Chinese Academy of Sciences, 325001 Wenzhou, Zhejiang, China

<sup>3</sup>Department of Engineering Mechanics, Institute of Biomechanics and Applications, Zhejiang University, 310007 Hangzhou, Zhejiang, China

<sup>4</sup>The First Clinical Medical College, Zhejiang Chinese Medical University, 310053 Hangzhou, Zhejiang, China

<sup>5</sup>Department of Psychiatry, Wenzhou Seventh People's Hospital, 325006 Wenzhou, Zhejiang, China

<sup>6</sup>Department of Acupuncture and Physiotherapy, The First Affiliated Hospital of Wenzhou Medical University, 325000 Wenzhou, Zhejiang, China

<sup>7</sup>Department of Acupuncture and Moxibustion, Zhejiang Hospital, 310013 Hangzhou, Zhejiang, China

<sup>8</sup>Department of Acupuncture, The Second Affiliated Hospital of Zhejiang Chinese Medical University, 310005 Hangzhou, Zhejiang, China

\*Correspondence: [zjyjqxq@163.com](mailto:zjyjqxq@163.com) (Xiaoqing Jin); [20214017@zcmu.edu.cn](mailto:20214017@zcmu.edu.cn) (Lihong Li)

Academic Editor: Bettina Platt

Submitted: 14 February 2025 Revised: 4 May 2025 Accepted: 14 May 2025 Published: 23 September 2025

## Abstract

**Background:** Pharmacological treatment for adolescent depression is limited in safety and efficacy. Acupuncture treatment for depression has been endorsed by the World Health Organization. This study aimed to analyze the efficacy and mechanisms of acupuncture in treating adolescent depression. **Methods:** An 4-week clinical trial was conducted from February 1, 2022 to June 30, 2024 at three hospitals. Patients aged 12 to 18 years were divided into three treatment groups: Manual acupuncture (MA), antidepressants (ADM), or acupuncture combined with antidepressants (MA+ADM). The 24-item Hamilton Depression scale (HAMD-24) scores, serum neurotransmitters levels, and resting-state functional magnetic resonance imaging (RS-fMRI) data were assessed at baseline (week 0) and after treatment (week 4). **Results:** After a 4-week intervention, both the MA and MA+ADM groups showed significant improvement in HAMD-24 scores. The MA+ADM group experienced more improvement, particularly in addressing somatization and sleep disorders. The study revealed that acupuncture increased serum levels of 5-hydroxytryptamine (5-HT), kynurenic acid, dopamine noradrenaline, adrenaline, L-histidine, and picolinic acid in adolescents with depression. Acupuncture was also found to regulate the excitability of depression-related brain regions (frontal lobe, caudate nucleus, anterior cingulate, and paracingulate gyri) and the functional connectivity of depression-related circuits (limbic-cortical-striatal-pallidal-thalamic circuit and hate circuit). Furthermore, significant negative correlations were observed between week 0 and week 4 HAMD-24 scores and up-regulated serum levels of 5-HT and dopamine. Scores were positively associated with increased amplitude of low-frequency fluctuations and regional homogeneity values. **Conclusions:** Acupuncture improves adolescents' depressive mood and sleep quality and alleviates somatic symptoms by modulating neurotransmitters levels and brain activity. **Clinical Trial Registration:** No: ChiCTR2200056171. <https://www.chictr.org.cn/showproj.html?proj=151197>.

**Keywords:** adolescent; depression; acupuncture; neurotransmitter agents; magnetic resonance imaging

## 1. Introduction

Adolescent depression has become the second leading cause of death among teenagers [1], with a prevalence of approximately 16% [2]. About 29% of these individuals exhibit suicidal ideation and 11% have attempted suicide [3]. The disorder imposes a tremendous socioeconomic and clinical burden, as patients often experience cognitive decline, reduced learning efficiency, substance abuse and suicide [4,5]. Current studies propose that the depression results from multiple factors, specifically: (1) imbalance of monoamine neurotransmitters; (2) the brain structure and function reorganization hypothesis; and (3) dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis [6]. However, the pathogenesis of adolescent depression and the biomarkers for predicting recurrence and evaluat-

ing efficacy are unclear. Moreover, the increase in drug variety forms an ever increasing “treatment-prevalence paradox” [7]. Therefore, finding safe and effective therapies is a compelling issue. Current guidelines provide evidence for the use of acupuncture in combination with medication for the treatment of adult depression, while adolescent depression primarily relies on psychotherapy and/or fluoxetine as the main treatment methods [8]. However, the efficacy and adherence of both therapies are limited, and concerns about medication tolerance and suicide risk persist [9,10].

The 2024 guidelines from the American Medical Association clearly recommend incorporating non-pharmacological therapies into depression management [11]. Acupuncture has been acknowledged by the World Health Organization since 2002 as an effective non-drug therapy for depression. Accumulating evidence suggests



that acupuncture is beneficial for various types of depression [12,13]. Furthermore, acupuncture has the potential to both enhance patient response to antidepressants and reduce their side effects [14–16]. However, research on acupuncture for adolescent depression remains relatively scarce. One pilot study found that three weeks of auricular acupuncture reduced repetitive self-injurious behavior in eight adolescents with depression, although it did not improve their depressive mood [17]. Other studies are limited to case reports and protocol explorations, employing interventions such as intradermal acupuncture and transcutaneous auricular vagus nerve stimulation, and lack clinical data and mechanistic research on the efficacy of traditional manual acupuncture [18–21]. A recent study shows that acupuncture alters the emotional responses of youth with self-reported depressive symptoms, suggesting the potential of acupuncture in adolescent depression [22]. Therefore, there is a need to conduct multi-center clinical trials to evaluate the efficacy of acupuncture for adolescent depression and to explore its mechanisms of action, which would provide valuable contributions to this field.

To address these issues, this study has two main objectives: (1) to evaluate the clinical efficacy of manual acupuncture (MA), antidepressant medication (ADM), and manual acupuncture combined with antidepressant medication (MA+ADM) on adolescent depression using the 24-item Hamilton Depression scale (HAMD-24) scores before and after treatment; (2) to explore the mechanisms of acupuncture treatment through a multidimensional analysis approach. Specifically, we compared the levels of serum neurotransmitters (such as tryptophan, tyrosine, and histidine) between the MA group and healthy control group (HCs). This comparison aimed to identify metabolic pathways associated with depression. Subsequently, we assessed the changes in serum neurotransmitters levels in the MA group before and after treatment to determine whether acupuncture could normalize these pathways. Then, we evaluated the changes in neuronal activity and functional connectivity in the brain using resting-state functional magnetic resonance imaging (RS-fMRI) data from the MA group before and after treatment. Additionally, we conducted Mendelian randomization (MR) analysis using large public databases to investigate the potential causal relationship between fMRI and depression risk.

## 2. Materials and Methods

### 2.1 Study Design and Patients

This clinical study was conducted at the Second Affiliated Hospital of Zhejiang Chinese Medical University, the First Affiliated Hospital of Wenzhou Medical University and Wenzhou Seventh People's Hospital from February 1, 2022 to June 30, 2024. The study patients included patients with depression who fulfilled the following criteria: (1) Age between 12 to 18 years; (2) Meeting the criteria of International Classification of Diseases 10 (ICD-10); (3)

Score of HAMD-24 greater than 20 points; (4) Agreement on informed consent signing; (5) Received a stable dose of antidepressant medication for at least four weeks prior to the start of the study in the groups of ADM and MA+ADM. Exclusion criteria included: (1) Secondary depression caused by drugs or organic psychosis; (2) Pregnant or lactating patients; (3) Treatment with antibiotics, steroids, or immunosuppressive agents two weeks before the assessment; (4) Severe suicidal or self-abusive tendencies; (5) Serious disease (such as heart, lung, liver, kidney dysfunction and infectious diseases).

A total of 150 adolescents diagnosed with depression and 50 age- and sex-matched HCs were recruited from local schools and communities via advertisements. The study was approved by the ethics committee of the Second Affiliated Hospital of Zhejiang Chinese Medical University (2021-KL-075-01), the First Affiliated Hospital of Wenzhou Medical University (KY2021-123) and Wenzhou Seventh People's Hospital (2022-Y26). All patients and their legal guardians provided written informed consent. The study registration code number (ChiCTR2200056171) was recorded with the Chinese Clinical Trial Registry (study registration date February 1, 2022).

### 2.2 Intervention

All patients were grouped according to their willingness. Patients in the MA group received a 30-minute treatment three times per week for four weeks. Treatment was performed by licensed acupuncturists with more than five years' experience. The acupuncture prescription was semi-standardized. The obligatory points were *Baihui* (DU20), *Yintang* (EX-HN3), *Zhongwan* (RN12), *Qihai* (RN6), *Tianshu* (ST25 bilateral), *Neiguan* (PC6 bilateral), *Zusanli* (ST36 bilateral) and *Taichong* (LR3 bilateral). In traditional Chinese medicine (TCM) theory, DU20, EX-HN3 and PC6 are commonly used to calm the spirit (*Shen*) and regulate mental disorders. RN12, RN6, ST25 and ST36 are key acupoints to regulate the *Middle and Lower Jiao*, helping to restore *Qi* balance and support digestion, which is considered essential for emotional stability. LR3 is a major *Liver meridian* point, often used to soothe *Liver Qi stagnation*, a core pattern of depression. Together, these points form a classical prescription to harmonize *Heart, Liver*, and *Spleen*, calm the *Shen*, and promote *Qi* circulation—key therapeutic strategies in managing depression from a TCM perspective. Adjunct acupoints were individualized by two senior TCM physicians—each with over five years of clinical experience—based on syndrome differentiation in accordance with TCM theory. Key TCM syndrome differentiation criteria are summarized in **Supplementary Table 1**. *Qimen* (LR14 bilateral) was used for the *syndrome of liver qi stagnation*, *Xingjian* (LR2 bilateral) for the *syndrome of stagnated qi transforming into fire*, *Fenglong* (ST40 bilateral) for the *syndrome of qi stagnation causing phlegm retention*, *Shaohai* (HT3 bilateral) and *Xinshu* (BL15 bilat-

eral) for the *syndrome of lack of heart spirit*, *Xinshu* (BL15 bilateral) and *pishu* (BL20 bilateral) are used for the *syndrome of heart-spleen deficiency*. *Shenshu* (BL23 bilateral) and *Taixi* (KI3 bilateral) for the *syndrome of yin-deficiency and fire-hyperactivity*. Disposable sterile acupuncture needles (0.25 × 40 mm, Hwato Brand, Suzhou, China) were used. The topographic mapping of acupuncture points are shown in **Supplementary Fig. 1** Patient counts for each syndrome differentiation and antidepressant are provided in **Supplementary Table 2**.

In this study, antidepressant therapy was restricted to Selective Serotonin Reuptake Inhibitors (SSRIs) only (fluoxetine, escitalopram, and sertraline), with all prescriptions and dosing overseen by board-certified psychiatrists. In principle, no medication changes or dose adjustments were permitted during the trial period. Prior to initiation, research assistants provided thorough education on the importance of adherence; during the study, regular follow-ups and assessments were conducted to monitor each participant's medication use, with reminders and interventions promptly delivered to those exhibiting poor adherence.

## 2.3 Measures

### 2.3.1 Clinical Assessments

HAMD-24 scores were assessed by board-certified psychiatrists with over five years of clinical experience in the diagnosis and treatment of adolescent depression. Both clinicians held national licensure in psychiatry and were responsible for evaluating the severity of depression at baseline (week 0, W0) and after treatment (week 4, W4). HCs were assessed according to HAMD-24 only at W0 to ensure they were not in depressive mood. Seven factors, were assessed, including: anxiety/somatization, cognitive impairment, sleep disturbance, retardation, weight, diurnal variation and feelings of despair. Higher scores indicate increased depression.

### 2.3.2 Enzyme-Linked Immunosorbent Assay (ELISA) Analysis

Blood samples were collected from 28 patients with depression at baseline and after treatment, while 28 HCs were randomly selected for blood samples collected at baseline. Serum samples were obtained after centrifugation (3000 rpm, 20 min) and immediately stored at −80 °C. Human ELISA Kits 5-Hydroxytryptamine (5-HT, CSB-E08363h, CUSABIO, Wuhan, Hubei, China), Dopamine (DA, CSB-E06888h, CUSABIO, Wuhan, Hubei, China), 4-Aminobutyric acid (GABA, EHJ-11108, HUIJIA BIOTECHNOLOGY, Xiamen, Fujian, China) were used to measure levels of the serum neurotransmitters, including 5-HT (ng/mL), DA (ng/mL) and GABA (μmol/g).

### 2.3.3 Neurotransmitters Analysis

Eight patient serum samples were collected before and after treatment and eight HC serum samples were sent for

ultra high performance liquid chromatography (UHPLC) and mass spectrometry (MS) analysis. All 23 different neurotransmitters were analyzed. The information of 23 neurotransmitters is shown in **Supplementary Table 3**. All serum samples were analyzed with the UHPLC-MS/MS system (ExionLC™ AD UHPLC-QTRAP® 6500+, AB SCIEX Corp., Boston, MA, USA). Processing parameters are given in the **Supplementary Material**.

### 2.3.4 Mendelian Randomization


Data on depression ( $n = 53,313$  cases and  $n = 394,756$  controls) were obtained from the FinnGen Biobank (<https://doi.org/10.5281/zenodo.5775047>). RS-fMRI data were obtained from Zhao *et al.* [23] in the UK Biobank (UKB) sample, which includes 191 phenotypes (75 amplitude traits that reflect regional spontaneous neural activity, 111 pairwise functional connectivity (FC) and 5 global FC). To ensure the accuracy of MR analysis, single-nucleotide polymorphisms significantly associated with RS-fMRI phenotypes were used as instrumental variables ( $p < 5 \times 10^{-8}$ ). Sensitivity and leave-one-out analyses are given in the **Supplementary Figs. 2–4**.

### 2.3.5 fMRI Analysis

MRI images of 11 patients were scanned before and after treatment on a SIEMENS 1.5T MRI system (Avanto, SQ engine, Siemens, Erlangen, Germany). Magnetization prepared rapid gradient echo sequence was used to obtain high-resolution 3D-T1WI anatomical images (parameters given in the **Supplementary Material**). Acquisition of both sequences required about eight minutes. During the MRI scan, patients were instructed to close their eyes, remain awake, stay relaxed, avoid thoughts and not move their head.

The RESTplus v1.24 (maintained at <http://www.restfmri.net/forum/restplus>) software package based on MATLAB R2017b (The MathWorks, Inc., Natick, MA, USA) was used for data preprocessing. Amplitude of low frequency fluctuations (ALFF), regional homogeneity (ReHo) and FC analysis were performed (procedures given in the **Supplementary Material**).

The brain regions with statistical differences in ALFF and ReHo values before and after acupuncture treatment were as follows: for ALFF, the right middle frontal gyrus (MFG.R), right superior frontal gyrus (SFG.R), right granular dorsolateral prefrontal cortex (dlPFC.R), right anterior cingulate and paracingulate gyri (ACG.R); for ReHo, the regions included MFG.R, SFG.R, dlPFC.R, ACG.R, the right caudate nucleus (CAU.R); and for MRI analysis, the regions were the temporal lobe, superior frontal gyrus (SFG), precuneus, angular and cingulate gyri. These regions were taken as regions of interest (ROI), and the peak value of ALFF and ReHo was at the position (33, 45, 33). In addition, for FC analysis, left superior frontal gyrus medial area 8 (SFG.L.7.1) (−5, 15, 54), left superior frontal gyrus me-



**Fig. 1. Clinical study flowchart.** HCs, healthy controls; MA, manual acupuncture; ADM, antidepressant medication; HAMD-24, 24-item Hamilton Rating Scale for Depression; 5-HT, 5-hydroxytryptamine; DA, dopamine; GABA, 4-aminobutyric acid; fMRI, functional magnetic resonance imaging.

dial area 6 (SFG.L.7.5) (−6, −5, 58), right superior frontal gyrus medial area 6 (SFG.R.7.5) (7, −4, 60) and left posterior parietal thalamus (THA.L.8.5) (−16, −24, 6) were also taken as ROIs [24]. Spherical regions with a six mm radius were taken as seed points to conduct the whole-brain FC analysis.

### 2.3.6 Statistical Analysis

Statistical analyses were performed using SPSS 23.0 (IBM SPSS Statistics for Windows, Version 23.0, IBM Corp., Armonk, NY, USA). Continuous variables were first evaluated for normality using the Shapiro-Wilk test and for homogeneity of variance using Levene's test. Variables meeting both criteria are presented as mean ± standard deviation (SD), while others are expressed as median (interquartile range [IQR]). For two-group comparisons of independent samples, Student's *t*-test was applied to normally distributed data and the Mann-Whitney U test to non-normal data; paired observations were analyzed using paired *t*-tests or Wilcoxon signed-rank tests as appropriate. Categorical variables are reported as counts (percentages) and compared via the chi-square test or Fisher's exact test.

Baseline clinical characteristics across all four groups (HCs, MA, ADM, MA+ADM) were compared. HAMD-24 total and factor scores at W0 and W4 were compared among the three patient groups (MA, ADM, MA+ADM): continuous measures satisfying ANOVA assumptions were analyzed by one-way analysis of variance with Tukey's

HSD post-hoc correction; otherwise, the Kruskal-Wallis H test with Dunn's post-hoc correction was used. Pairwise comparisons of categorical variables were Bonferroni-adjusted. Spearman's rank correlation assessed relationships between HAMD-24 scores and serum neurotransmitters levels, ALFF values, and ReHo values. Differences and correlations will be considered statistically significant at a *p*-value < 0.05. Gaussian random field theory (GRF) was used for multiple comparisons in neuroimaging data (voxel-level *p*-value < 0.05, cluster-level *p*-value < 0.05, two-tailed test).

## 3. Results

### 3.1 Demographic and Clinical Characteristics of patients

A total of 150 depressed adolescents and 50 matched HCs were recruited (Fig. 1). The demographic and clinical characteristics of all individuals are summarized in Table 1. HAMD-24 scores and disease duration of patients were not significantly different among the three intervention groups. Statistically significant differences (*p* < 0.001) were found between patients and HCs across family problems, interpersonal relationship/emotional problems and other events (including economic problem, traumatic life events and seasonal variation). No significant difference was found among the four groups for age, sex, body mass index (BMI), somatotype, educational attainment, smoking status, alcohol consumption and study/work problems.



**Table 1. Characteristics of study patients.**

Characteristics	HCs (n = 50)	MA (n = 50)	ADM (n = 50)	MA+ADM (n = 50)	p-value <sup>a</sup>
Age, M (P <sub>25</sub> , P <sub>75</sub> ), y	16.0 (14.75, 17.00)	16.0 (15.00, 17.00)	16.0 (14.00, 17.00)	16.0 (15.00, 17.00)	0.837
Sex, n (%)					0.423
Male	21 (42.00)	15 (30.00)	15 (30.00)	14 (28.00)	
Female	29 (58.00)	35 (70.00)	35 (70.00)	36 (72.00)	
Duration of depression, mean (SD), y	NA	1.91 (1.23)	2.08 (1.21)	1.68 (0.84)	0.194 <sup>b</sup>
BMI, mean (SD), kg/m <sup>2</sup>	20.72 (2.66)	20.89 (3.45)	20.57 (3.30)	20.18 (3.07)	0.707
Somatotype, n (%)					0.895
Thin	11 (22.00)	13 (26.00)	11 (22.00)	15 (30.00)	
Normal	31 (62.00)	28 (56.00)	33 (66.00)	27 (54.00)	
Overweight/Fat	8 (16.00)	9 (18.00)	6 (12.00)	8 (16.00)	
Educational attainment, n (%)					0.849
Junior high school and below	18 (36.00)	16 (32.00)	18 (36.00)	13 (26.00)	
Senior high school	23 (46.00)	24 (48.00)	26 (52.00)	28 (56.00)	
College and above	9 (18.00)	10 (20.00)	6 (12.00)	9 (18.00)	
Smoking status, n (%)					0.910
Not smoking	45 (90.00)	43 (86.00)	44 (88.00)	45 (90.00)	
Smoke regularly	5 (10.00)	7 (14.00)	6 (12.00)	5 (10.00)	
Alcohol consumption, n (%)					0.253
No alcohol	42 (84.00)	42 (84.00)	47 (94.00)	46 (92.00)	
Drink regularly	8 (16.00)	8 (16.00)	3 (6.00)	4 (8.00)	
Stressful events, n (%)					
Family problems	12 (24.00)	32 (64.00)*	39 (78.00)*	33 (66.00)*	<0.001
Study/work problems	36 (72.00)	42 (84.00)	39 (78.00)	43 (86.00)	0.290
Interpersonal relationship/Emotional problems	17 (34.00)	33 (66.00)*	29 (58.00)	32 (64.00)*	0.004
Other events	16 (32.00)	31 (62.00)*	30 (60.00)*	29 (58.00)	0.008
HAMD-24 scores <sup>c</sup> , mean (SD)	4.22 (1.89)	27.70 (10.63)	26.82 (5.85)	28.14 (9.33)	0.749 <sup>b</sup>

SD, standard deviation; BMI, body mass index. <sup>a</sup> Calculated using a one-way analysis of variance (*p*-value based on the Tukey adjustment in pairwise comparison based on data distribution) or Chi-square test (*p*-value based on the Bonferroni adjustment in pairwise comparison).

<sup>b</sup> HCs group were not analyzed with other three groups. <sup>c</sup> Score range is from 0 to 76, with higher scores indicating more serious depression.

\**p* < 0.05 compared with HCs group.

### 3.2 HAMD-24 Scores and HAMD-24 Factor Scores of Adolescents With Depression

Table 2 presents the pre- and post-treatment changes in HAMD-24 total and factor scores for all patients. There was significant reduction (*p* < 0.001 for all) in HAMD-24 scores and factor scores in all three groups. Compared with the post-MA group, patients in the post-MA+ADM group had significantly lower HAMD-24 scores (*p* = 0.021). Moreover, significant reductions in anxiety/somatisation and sleep disturbance scores were observed in the post-MA+ADM group compared with the post-MA and post-ADM groups (*p* < 0.001), while no significant difference were found among the three groups in the remaining five factor scores (cognitive impairment, retardation, weight, diurnal variation and feelings of despair).

### 3.3 Serum 5-HT, DA, GABA Levels in Adolescents With Depression Versus HCs

Patients in the ADM and MA+ADM groups included in this study had been taking different types and doses of

antidepressants for at least one month. Antidepressants are known to work by altering neurotransmitters levels and may have a greater effect on serum neurotransmitters levels [25]. Therefore, this study focused on the detection of serum neurotransmitters levels in the HC and MA groups to observe the effect of acupuncture treatment on serum neurotransmitters.

Table 3 shows serum levels of 5-HT, DA and GABA in HCs and adolescents with depression in the MA group before and after acupuncture treatment. Compared with patients in the pre-treatment group, 5-HT and DA serum levels were significantly increased in patients in the post-treatment group (*p* < 0.001), although the serum 5-HT levels were still lower than those in the HCs group (*p* < 0.05). Note that patients in the pre-treatment group showed lower 5-HT and DA serum levels than those of the HCs group (*p* < 0.001). No significant difference was found in serum DA levels between the post-treatment and HCs groups (*p* > 0.05). Neither was any significant difference found in GABA concentration among the groups.

**Table 2. HAMD-24 scores of adolescents with depression during the study.**

Outcome Measure	MA (n = 50)	ADM (n = 50)	MA+ADM (n = 50)	F/H	p-value <sup>a</sup>
HAMD-24 scores <sup>c</sup> , mean (SD)/median (quartile 1-quartile 3)					
Week 0	27.70 (10.63)	26.82 (5.85)	28.14 (9.33)	0.289	0.749 <sup>b</sup>
Week 4	17.00 (12.00, 25.00) <sup>####</sup>	16.76 (6.09) <sup>###</sup>	13.60 (6.46) <sup>###</sup>	8.741	0.013
Seven factor scores of HAMD-24					
Factor 1: Anxiety/Somatisation					
Week 0	7.00 (5.00, 8.00)	6.66 (1.85)	6.70 (3.02)	0.113	0.945
Week 4	4.50 (3.00, 6.00) <sup>#####</sup>	4.54 (1.57) <sup>#####</sup>	2.00 (1.00, 4.00) <sup>###</sup>	33.276	<0.001
Factor 2: Cognitive impairment					
Week 0	6.00 (3.00, 8.00)	4.90 (2.31)	6.00 (2.99)	3.928	0.140
Week 4	3.00 (2.00, 6.00) <sup>###</sup>	3.00 (2.00, 5.00) <sup>###</sup>	3.00 (1.75, 5.00) <sup>###</sup>	3.141	0.208
Factor 3: Sleep disturbance					
Week 0	3.22 (1.76)	4.00 (2.00, 5.00)	3.50 (2.00, 5.00)	2.313	0.315
Week 4	3.00 (2.00, 4.00) <sup>#####</sup>	2.00 (1.00, 3.00) <sup>#####</sup>	0.50 (0.00, 2.00) <sup>###</sup>	56.559	<0.001
Factor 4: Retardation					
Week 0	5.00 (3.75, 7.00)	5.00 (4.00, 6.00)	5.30 (2.11)	1.357	0.507
Week 4	3.00 (2.00, 4.00) <sup>###</sup>	3.00 (2.00, 4.25) <sup>###</sup>	3.00 (2.00, 4.00) <sup>###</sup>	2.874	0.238
Factor 5: Weight					
Week 0	1.00 (0.00, 1.25)	1.00 (1.00, 1.00)	1.00 (0.00, 1.00)	0.524	0.769
Week 4	0.00 (0.00, 0.00) <sup>###</sup>	0.00 (0.00, 0.00) <sup>###</sup>	0.00 (0.00, 0.00) <sup>###</sup>	1.956	0.376
Factor 6: Diurnal variation					
Week 0	1.00 (0.00, 2.00)	1.00 (0.00, 1.00)	1.00 (1.00, 2.00)	5.622	0.060
Week 4	0.00 (0.00, 1.00) <sup>###</sup>	1.00 (0.00, 1.00) <sup>###</sup>	1.00 (0.00, 1.00) <sup>###</sup>	2.110	0.348
Factor 7: Feelings of despair					
Week 0	5.00 (3.00, 6.00)	4.00 (3.75, 6.00)	4.64 (2.27)	0.109	0.947
Week 4	3.00 (2.00, 4.00) <sup>###</sup>	2.50 (2.00, 3.00) <sup>###</sup>	3.00 (2.00, 4.00) <sup>###</sup>	1.274	0.529

<sup>a</sup> Kruskal-Wallis H test was used to compare the three groups. <sup>b</sup> A one-way analysis of variance (*p*-value based on the Tukey adjustment in pairwise comparison based on data) was used to compare the three groups. <sup>c</sup> Score range is from 0 to 76, with higher scores indicating more serious depression. \**p* < 0.05, \*\*\**p* < 0.001 compared with MA+ADM group. ####*p* < 0.001 compared with the same group in week 0.


### 3.4 Neurotransmitters Analysis Revealed Significant Differences Between Adolescents With Depression and HCs

Based on literature [6], we focused on four neurotransmitters pathways closely associated with depression: the tryptophan-5-HT, tyrosine-DA/noradrenaline (NE), histidine-histamine (HisA), and glutamate-GABA pathways. Initial ELISA results revealed significant differences in 5-HT and DA levels both between and within groups, underscoring their potential role in adolescent depression. To further investigate whether acupuncture modulates a broader spectrum of neurotransmitter pathways, we subsequently conducted targeted UHPLC-MS/MS analysis of 23 neurotransmitters in serum samples collected at W0 and W4 from 8 HCs and 8 patients who received MA treatment. Eighteen kinds of neurotransmitters were identified, of which 10 showed significant difference among three groups (Fig. 2), including 5-HT, DA (found in section 3.3). When compared to HCs group, the pre-treatment group showed distinctly lower level in serum 5-HT, 5-hydroxyindole-3-acetic acid (5-HIAA), kynurenic acid (KynA), NE, L-histidine (His) and acetylcholine chlo-

ride (Acetyl-CoA). After treatment, the serum 5-HT, KynA, DA, NE, adrenaline (E), His and picolinic acid (PA) levels increased compared to the pre-treatment group. The serum 5-HIAA and Acetyl-CoA levels of post-treatment were significantly lower, while serum DA and HisA levels of the post-treatment were higher, compared with those in HCs group. No difference was detected in GABA, L-tryptophan, DL-kynurenine (Kyn), L-tyrosine (Tyr), levodopa, L-glutamic acid (Glu), L-glutamine and xanthurenic acid.

### 3.5 Mendelian Randomization Reveals Causal Links Between Depression and RS-fMRI Phenotypes

An MR analysis found that increased FC between the temporal lobe and inferior frontal gyrus (IFG) reduced the risk of depression (Inverse-Variance Weighted Odds Ratio (IVW OR) = 0.88, 95% Confidence Interval (CI): 0.80–0.96, *p* = 0.004). Additionally, it was found that enhanced neural connection activity in SFG and IFG was associated with a lower risk of depression (IVW OR = 0.79, 95% CI: 0.68–0.92, *p* = 0.003). Further analysis revealed that higher FC of the temporal lobe, frontal lobe or supplementary mo-



**Fig. 2. Serum levels of neurotransmitters in healthy controls and patients with depression before and after acupuncture treatment.** (a) Eleven kinds of neurotransmitters involved in tryptophan metabolism. (b) Five kinds of neurotransmitters involved in histidine and glutamate metabolism. (c) Seven kinds of neurotransmitters involved in tyrosine metabolism. The neurotransmitters within blue boxes were detected. #  $p < 0.05$ , ##  $p < 0.01$  when compared with the pre-treatment group; \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$  when compared with HCs. W0, pre-treatment group; W4, post-treatment group. The arrows represent biochemical conversion relationships among neurotransmitters in the corresponding metabolic pathways. Trp, L-tryptophan; Kyn, DL-kynurenine; KynA, kynurenic acid; 5-HIAA, 5-hydroxyindole-3-acetic acid; XA, xanthurenic acid; Acetyl-CoA, acetylcholine chloride; PA, picolinic acid; Tyr, L-tyrosine; DOPA, levodopa; NE, noradrenaline; E, adrenaline; His, L-histidine; Glu, L-glutamic acid; HisA, histamine; Gln, L-glutamine.

tor area and frontal lobe was inversely related to depression risk (IVW OR = 0.81, 95% CI: 0.72–0.92,  $p = 0.001$ ). Conversely, it was discovered that increased FC between precuneus, angular gyrus or cingulate and temporal lobe elevated the risk of depression (IVW OR = 1.17, 95% CI: 1.03–1.32,  $p = 0.012$ ). It is also noted that higher connectivity in the global measure of the default mode network (DMN) was associated with a heightened risk of depression (IVW OR = 1.06, 95% CI: 1.00–1.13,  $p = 0.044$ ). Finally, findings indicated that increased activity in the calcarine,

lingual or cuneus and paracentral or postcentral regions was linked to a decreased risk of depression (IVW OR = 0.93, 95% CI: 0.87–1.00,  $p = 0.040$ ) (Fig. 3).

### 3.6 Longitudinal RS-fMRI Changes Following Acupuncture Treatment

Compared to the pre-treatment group, patients after treatment showed significantly lower ALFF and mKccReHo values in MFG.R, SFG.R, dlPFC.R, and ACG.R (Fig. 4a,b, Table 4). Additionally, the mKccReHo value of the CAU.R in the post-treatment group was significantly


**Table 3. Serum levels of 5-HT, DA and GABA in healthy controls and adolescents with depression before and after acupuncture treatment.**

Group	Serum neurotransmitters levels		
	5-HT (ng/mL)	DA (ng/mL)	GABA ( $\mu$ mol/g)
HCS (n = 28)	237.09 (46.01)	58.50 (17.69)	1.44 (0.26)
pre-treatment (n = 28)	111.88 (35.53, 225.70)***	25.87 (12.42)***	1.46 (1.30, 1.75)
post-treatment (n = 28)	177.71 (59.32, 289.56)####	47.81 (24.42)###	1.30 (1.23, 1.49)

All data were expressed as mean ( $\pm$  standard deviation, SD) or median (quartile 1-quartile 3).

#### $p < 0.001$  compared with the pre-treatment group; \* $p < 0.05$ , \*\*\* $p < 0.001$  compared with

HCS group. HCS, Healthy Controls.



**Fig. 3. Forest plot of the causal association between RS-fMRI and depression.** SNP, single-nucleotide polymorphisms; OR, odds ratio; MR, Mendelian randomization; IVW, inverse variance weighted; CI, confidence interval; RS-fMRI, resting-state functional magnetic resonance imaging.

reduced (Fig. 4b, Table 4). These results suggest that the excitability of the above brain regions would be reduced after acupuncture treatment.

In agreement with the partial aforementioned MR estimates, the post-treatment patients exhibited increased FC between the temporal lobe and IFG, SFG and IFG, as well as between the temporal lobe and the frontal lobe, when compared to their pre-treatment state (Table 5).

For ROI-whole brain connectivity (Fig. 4c, Table 5), post-treatment patients showed decreased FC when compared to pre-treatment in terms of MFG.R connectivity with clusters including the right inferior parietal lobule (IPL.R), right precuneus (PCUN.R) and right temporal lobe. These regions showing significant changes after acupuncture treatment are mainly within the DMN, which was a causal risk factor for depression in this MR analysis.



**Table 4. Brain regions with significant ALFF and ReHo differences in adolescents with depression before and after acupuncture treatment.**

Coordinate regions	Cluster size	Peak T value	MNI coordinate (mm)		
			X	Y	Z
ALFF					
MFG.R, SFG.R, dlPFC.R, ACG.R	456	−3.8082	33	45	33
ReHo					
MFG.R, SFG.R, dlPFC.R, ACG.R, CAU.R	358	−3.6502	33	45	33

ALFF, the amplitude of low-frequency fluctuations; MNI, Montreal Neurological Institute; Gaussian random field (GRF) correction, voxel-level  $p < 0.05$ , cluster-level  $p < 0.05$ , two-tailed test. ReHo, regional homogeneity.

**Table 5. Functional connectivity differences in adolescents with depression between before and after acupuncture treatment.**

ROI	Coordinate regions	Cluster size	Peak T value	MNI coordinate (mm)		
				X	Y	Z
STG.L.6.4	IFG, Frontal Gyrus (MR related FC)	512	4.2077	−42	21	12
STG.L.6.6	IFG, Frontal Gyrus (MR related FC)	189	3.7442	−33	36	−21
SFG.R.7.7	IFG (MR related FC)	235	3.5071	−18	30	−27
MFG.R	IPL.R, PCUN.R, right temporal lobe (DMN) (MR related FC)	446	−4.1908	48	−51	36
SFG.L.7.1	IFG (MR related FC)	869	3.8338	42	9	−6
	INS.R, PUT.R (hate circuit)					
SFG.L.7.5	IFG (MR related FC)	255	3.9593	−42	24	−3
	INS.L, PUT.L (hate circuit)					
SFG.R.7.5	IFG (MR related FC)	310	4.604	−30	39	−9
	INS.L, PUT.L (hate circuit)					
THA.L.8.5	PUT.R, right limbic lobe, right frontal lobe, SFG.R (orbital part), CAU.R, PAL.R (LCSPT circuit)	177	−3.993	27	9	−6

STG.L, left superior temporal gyrus; IFG, inferior frontal gyrus; PCUN.R, right precuneus; DMN, default mode network; PAL.R, right pallidum; LCSPT, limbic-cortical-striatal-pallidal-thalamic.

Another area with decreased FC was located in the left posterior parietal thalamus (THA.L.8.5) area extending into the right putamen (PUT.R), right limbic lobe, right frontal lobe, right caudate (CAU.R) and right pallidum (PAL.R). These structures are predominantly components of the limbic-cortical-striatal-pallidal-thalamic (LC-SPT) circuit. Post-treatment patients exhibited enhanced bilateral SFG connections with insula (INS) and putamen (PUT), which are primarily part of a hate circuit.

### 3.7 Correlations Between HAMD-24 Scores and Serum 5-HT Levels, Serum DA Levels, ALFF Values and ReHo Values of Adolescents With Depression


Spearman correlation analysis was used to further explore correlations between HAMD-24 scores and serum 5-HT levels, serum DA levels, ALFF values and ReHo values of patients with depression (Fig. 5). It was found that the HAMD-24 scores of patients at W0 and W4 showed significant negative correlations with up-regulated serum 5-HT and DA levels, while they had a positive correlation with the ALFF and ReHo values of SFG.R, dlPFC.R and ACG.R.

## 4. Discussion


This study shows that a four-week course of acupuncture significantly improves depressive symptoms in depressed adolescent patients. The efficacy likely arises from increased serum levels of 5-HT, DA, KynA, NE, E, His and PA, decreased functional connectivity in the DMN and LCSPT networks and strengthened connectivity in a hate circuit. Furthermore, HAMD-24 scores are closely correlated with 5-HT, DA, ALFF and ReHo. No serious adverse events were reported in our study.

### 4.1 Acupuncture Improves Depression in Adolescents: Notable Synergy With Antidepressants

Twelve acupuncture sessions over four weeks reduced HAMD-24 scores in adolescents with depression and the synergy with antidepressants is significant. Acupuncture also alleviates anxiety/somatization and sleep disorders in depressed adolescent patients, with more pronounced effects in the MA+ADM group, exceeding those of either MA or ADM alone. These findings are consistent with recent studies [12,26]. Four weeks of acupuncture significantly alleviated depression and insomnia [27], while six



**Fig. 4. Differences of ALFF, ReHo and FC in adolescents with depression before and after acupuncture treatment.** (a) Compared with patients before acupuncture treatment, reduced ALFF values in the MFG.R, SFG.R, dIPFC.R and ACG.R were observed in patients after treatment. (b) Compared with patients before acupuncture treatment, reduced mKccReHo values in the MFG.R, SFG.R, dIPFC.R, ACG.R and CAU.R were observed in patients after treatment. (c) Compared with patients before acupuncture treatment, patients after treatment show two negative connections: between MFG.R and IPL.R (purple line), between THA.L.8.5 and PUT.R (blue line); and patients before treatment show three positive connections: between SFG.L.7.1 and INS.R (red line), between SFG.L.7.5 and INS.L (yellow line), as well as between SFG.R.7.5 and INS.L (green line). (a,b) Red and blue denote higher and lower ALFF or mKccReHo respectively and the color bars indicate the T value from two-tailed tests. ALFF, amplitude of low-frequency fluctuations; ReHo, regional homogeneity; mKccReHo, mean Kendall coefficient of concordance regional homogeneity; MFG.R, right Middle Frontal Gyrus; SFG.R, right Superior Frontal Gyrus; dIPFC.R, right dorsolateral Prefrontal Cortex; ACG.R, right Anterior cingulate and paracingulate gyri; CAU.R, right Caudate nucleus; FC, functional connectivity; IPL.R, right Inferior Parietal Lobule; THA.L, left Thalamus; PUT.R, right putamen; SFG.L, left Superior Frontal Gyrus; INS.R, right Insula; INS.L, left Insula.



**Fig. 5.** Correlations between HAMD-24 scores and (a) serum 5-HT levels, (b) Serum DA levels, (c) ALFF, and (d) ReHo in adolescents with depression.

weeks of acupuncture combined with SSRIs showed superior improvements in anxiety, somatization and sleep disturbances when compared to SSRIs alone [14,28]. The synergistic effect of acupuncture has been preliminarily validated [14,29–31]. Although this study did not include a predefined medication tapering assessment protocol, psychiatrists reported a faster medication tapering trend among some patients in the MA+ADM group who voluntarily continued acupuncture treatment post-trial. This observational phenomenon requires validation through prospective studies with standardized tapering protocols.

#### 4.2 Acupuncture Alleviates Adolescent Depression Symptoms by Regulating Serum Neurotransmitters Levels

Depression is associated with dysregulation in the neurotransmitters systems, including the serotonin and dopamine pathways [32]. Results reported here suggest that acupuncture affected serum neurotransmitters regulation in adolescents with depression and involved the tyrosine (DA, NE and E), tryptophan (5-HT, 5-HIAA, KynA and PA) and histidine (His and HisA) pathways.

These findings are consistent with previous studies. Specifically, for the tyrosine metabolic pathway, the levels of DA, NE and E could be improved by acupuncture in depressed patients and animal models [33,34]. These neurotransmitters are frequently found at reduced levels in the serum of patients diagnosed with depression. Moreover, PC6 stimulation has been demonstrated to reverse anhedonia and to markedly suppress c-fos expression within the hypothalamic paraventricular nucleus [35].

For the tryptophan metabolic pathway, the levels of 5-HT, 5-HIAA, KynA and PA of patients before the treatment were lower than those in the HCs group. For instance, recent studies have found that the levels of PA in plasma and cerebrospinal fluid were lower in depressed patients [36–39] and this state had persisted in the cerebrospinal fluid of patients who had attempted suicide for a duration exceeding more than two years [40]. The current study showed that the levels of those transmitters could be significantly increased by acupuncture treatment. Further research indicated that the combined stimulation of DU20,

ST36, and CV12 upregulated the 5-HT system, promoted gastrointestinal motility, and repaired synaptic damage in the hippocampus [41]; moxibustion at ST25, CV6, and DU20 regulated the kynurenine metabolic pathway along the gut-brain axis, inhibited overactivation of microglia and neurons in the hippocampus, and improved depressive-like behaviors [42]. Additionally, electroacupuncture at ST36 and ST25 exerted antidepressant effects by modulating the gut microbiota and neurotransmitter systems [43]. Finally, electroacupuncture at LR3 modulated the cerebral kynurenine pathway, decreased proinflammatory cytokines and glutamate release [44].

For the histidine metabolic pathway, it was found that the level of His in patients before treatment was lower than that in HCs group and it increased after acupuncture treatment. Studies have shown that His deficiency can be used as a predictor of moderate depressive symptoms in older women [45]. In the current study, it was found that HisA levels tended to be elevated in the pre-treatment group but were significantly higher after acupuncture treatment when compared to a HCs group, which may be related to the involvement of HisA in the regulation of brain 5-HT, DA and NE systems, as well as the immune system [46].

### 4.3 Acupuncture Modulates Brain Function in Adolescents With Depression

#### 4.3.1 Acupuncture Suppresses the Functional Activity of the Frontal Limbic System in Adolescents With Depression

The RS-fMRI technology measures brain neuron activity and synchronicity, aiding in evaluating acupuncture's effects on depression. While many studies focus on adults, adolescent depression may involve different mechanisms due to incomplete neurodevelopment. Thus, analyzing RS-fMRI changes in adolescents before and after acupuncture is crucial. Higher ALFF values represent stronger neuronal activity and higher ReHo values represent greater synchronization of local neuronal activity. The frontal lobe is an important part of the cognitive control network and is involved in emotion regulation and cognitive execution. The ACG is a limbic structure involved in the processing of emotional and reward information. The CAU is involved in the brain's reward system and is associated with the dopamine system and its dysfunction causes anhedonia. Depressed patients have elevated fALFF in the prefrontal lobe, ACG, SFG and MFG [47]. The current study found that acupuncture decreased the ALFF and ReHo values of the MFG.R, SFG.R, dlPFC.R and ACG.R and also decreased the ReHo value of CAU.R. These changes mainly occurred in the right cerebral hemisphere. A positive correlation between ALFF and ReHo values and HAMD-24 scores was also found, suggesting that acupuncture could balance neuronal activity and local consistency in the aforementioned brain regions of adolescents with depression, which is consistent with the results of acupuncture treatment for depression in

adults [48,49] and elderly people [50]. Notably, stimulation of LR3 might exert antidepressant effects by enhancing frontal-lobe function [51]. Antidepressants and acupuncture somehow have a consistent regulatory effect on the SFG and MFG. Additionally, acupuncture also regulates CAU dysfunction when compared to antidepressants. Such results support the existing results of the role of the frontal limbic system in the pathogenesis of adolescent depression and that acupuncture treatment reverses the abnormal activity of the frontal limbic system [52].

#### 4.3.2 Acupuncture Improves Functional Connectivity of Depression-related Brain Regions in Adolescents With Depression

In the MR study reported here, elevated FC between the temporal lobe and the inferior frontal, superior frontal and inferior frontal gyri, as well as the temporal and frontal lobes, were identified as protective factors against depression. After acupuncture treatment, the FC within these specified brain regions was observed to have increased. This study found no significant effect of acupuncture on the regulation of FC between the precuneus or cingulate and temporal lobe, which has been found to be enhanced in depressed patients. No effect of acupuncture was found on the regulation of neural activities of the calcarine cortex, lingual gyrus, cuneus, postcentral gyrus and precentral gyrus. It is speculated that this discrepancy may be the result of participant variability.

The DMN is thought to be involved in emotional and cognitive function and previous studies have confirmed over-connectivity within the DMN in depressed patients [53–57], with similar findings in adolescent depression [58,59]. The DMN may be a potential target for the treatment of depression, which can be normalized by transcranial magnetic stimulation [60]. MR suggested that increased connectivity of the DMN causes higher depression risk. In the current study, the FC between the MFG.R and IPL.R, PCUN.R and temporal lobes were found to be weakened by the acupuncture treatment in depressed patients, suggesting that acupuncture reduced the connections within the DMN. Other studies found that electro-acupuncture at the *Baihui* point suppressed DMN overactivation [61,62].

The LCSPT circuit is considered to be an important circuit in the pathogenesis of depression [63]. Structural and functional changes in LCSPT circuits are likely to be highly reliable markers of depression diagnosis [64,65]. The amygdala is located in the limbic system and is involved in a variety of emotional processes. When the pathological activity of the amygdala increases, abnormal activity of the LCSPT circuit might occur [66]. Additionally, it was found that by cutting off the projection of the amygdala to the LCSPT circuit, patients with treatment-resistant depression were less likely to relapse into depression [67,68]. It can be seen that there is a close relationship between the amygdala and LCSPT circuits. This study showed that in



the resting state of the brain of patients after acupuncture, the FC of the LCSPT circuit were weakened when compared with that found prior to treatment, including in the right limbic lobe, right frontal lobe, SFG.R (orbital part), PUT.R, PAL.R and THA.L, in addition to the amygdala. Both monoamine-targeted antidepressants and electroconvulsive therapy reverse structural abnormalities in LCSPT circuits [69–71]. Several studies have even suggested that regulating the LCSPT circuits may be the central mechanism of acupuncture treatment for depression [29,72,73]. It is worth mentioning that Glu is an excitatory neurotransmitter that exhibits elevated transmission in the LCSPT circuits of depressed patients [74], which is consistent with the trend found here in the mass spectrometry analysis.

When using bilateral SFG as the seed points for whole-brain FC analysis, this study found that the FC of a hate circuit was enhanced in adolescents with depression after acupuncture, mainly involving the functional regions SFG, INS and PUT. INS and PUT are involved in the perception of contempt and hate [75,76]. It was first proposed in 2013 that the FC of hate circuits was weakened in patients with depression. If the hate circuit is damaged, patients would have less cognitive control over their emotions and have difficulty in controlling negative thoughts, such as self-loathing or hatred of external circumstances. Several subsequent studies have found similar results, including a decrease in FC inside the PUT [75,77–81]. Given that adolescents with depression are prone to resentment, it is speculated here that changes in a hate circuit may play an important role in both the pathogenesis and treatment of adolescent depression and acupuncture may provide a better treatment option.

This study preliminarily reveals the potential mechanisms of acupuncture in treating depression in adolescents. However, several limitations should be acknowledged. There was no sham acupuncture control group, making it difficult to isolate non-specific effects. The effects of acupuncture may be influenced by psychosocial factors such as patient expectations, doctor-patient interactions, and procedural rituals. Future research should introduce standardized sham acupuncture devices and evaluator blinding, quantify patient expectations, and monitor neurotransmitter and brain function changes to analyze the specific mechanisms of acupuncture and reduce bias from placebo effects. Additionally, the limited sample size leads to insufficient statistical power and a risk of Type II errors, which may affect the accuracy of the results. The lack of tracking long-term efficacy and changes in biological markers also limits the assessment. Subsequent studies should be conducted within a multi-center, large-sample, long-follow-up framework, employing rigorous control designs and multimodal biomarker analyses to validate the reliability and generalizability of the research findings.

## 5. Conclusions

In this study, it was shown that acupuncture treatment had a significant effect on depression in adolescents. Additionally, it was found that four weeks of acupuncture combined with antidepressants was superior to either acupuncture or antidepressants alone, thus showing significant advantages of acupuncture in improving the anxiety/somatization and sleep disorders of patients. The study showed that acupuncture increased the levels of serum 5-HT, KynA, DA, NE, E, His and PA in adolescents with depression, supports a causal relationship between depression and RS-fMRI and that acupuncture modulates the level of excitability of emotion-related brain regions (including frontal lobe, CAU and ACG) and the FC of depression-related circuits (DMN, LCSPT circuit and a hate circuit). Further, a correlation was found between HAMD-24 scores and the mechanism-related objective indicators studied. Results confirm the efficacy of acupuncture in treating adolescent depression, suggesting potential mechanisms through the regulation of HAMD-24 factor scores, serum neurotransmitters levels and RS-fMRI findings. This provides a degree of evidence supporting acupuncture as a viable treatment for adolescent depression.

## Availability of Data and Materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

## Author Contributions

JLJ: Investigation, Conceptualization, Methodology, Data curation, Project administration, Supervision, Formal analysis, Funding acquisition, Writing—original draft, Writing—review & editing. BHJ: Conceptualization, Supervision, Writing—reviewing and editing, Project administration. WJ: Formal analysis, Data curation, Project administration, Writing—review & editing. PYZ: Investigation, Data curation, Project administration, Writing—review & editing. HRC: Conceptualization, Investigation, Resources, Data Curation, Supervision, Project Administration, Writing—review & editing. WJC: Conceptualization, Investigation, Resources, Data Curation, Supervision, Project Administration, Writing—review & editing. XQJ: Methodology, Funding acquisition, Supervision, Writing—reviewing and editing. LHL: Methodology, Funding acquisition, Resources, Supervision, Writing—reviewing and editing. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

## Ethics Approval and Consent to Participate

Our study was carried out in accordance with the guidelines of the Declaration of Helsinki and approved by the ethics committee of the Second Affiliated Hospital of

Zhejiang Chinese Medical University (2021-KL-075-01), the First Affiliated Hospital of Wenzhou Medical University (KY2021-123) and Wenzhou Seventh People's Hospital (2022-Y26). All patients and their legal guardians provided written informed consent.

## Acknowledgment

We would like to thank all the patients who made it possible for us to conduct this study.

## Funding

The study is supported by Administration of Traditional Chinese Medicine of Zhejiang Province (No. 2022ZQ072); Key Research and Development Project of Zhejiang Province (No. 2024C03208); Inheritance Studio of the Xiaoqing Jin Famous Chinese Medicine Experts in China (Grant number 2022 No.75); Inheritance Studio of Xiaoqing Jin Famous Chinese Medicine Experts in Zhejiang Province (Grant number GZS2021011).

## Conflict of Interest

The authors declare no conflict of interest.

## Supplementary Material

Supplementary material associated with this article can be found, in the online version, at <https://doi.org/10.31083/JIN38071>.

## References

- [1] Hua LL, Lee J, Rahmandar MH, Sigel EJ, COMMITTEE ON ADOLESCENCE, COUNCIL ON INJURY, VIOLENCE, AND POISON PREVENTION. Suicide and Suicide Risk in Adolescents. *Pediatrics*. 2024; 153: e2023064800. <https://doi.org/10.1542/peds.2023-064800>.
- [2] Daly M. Prevalence of Depression Among Adolescents in the U.S. From 2009 to 2019: Analysis of Trends by Sex, Race/Ethnicity, and Income. *The Journal of Adolescent Health*. 2022; 70: 496–499. <https://doi.org/10.1016/j.jadohealth.2021.08.026>.
- [3] Joyce NR, Schuler MS, Hadland SE, Hatfield LA. Variation in the 12-Month Treatment Trajectories of Children and Adolescents After a Diagnosis of Depression. *JAMA Pediatrics*. 2018; 172: 49–56. <https://doi.org/10.1001/jamapediatrics.2017.3808>.
- [4] Clayborne ZM, Varin M, Colman I. Systematic Review and Meta-Analysis: Adolescent Depression and Long-Term Psychosocial Outcomes. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2019; 58: 72–79. <https://doi.org/10.1016/j.jaac.2018.07.896>.
- [5] Sagatun Å, Wentzel-Larsen T, Heyerdahl S, Lien L. Mental health in adolescence and subsequent receipt of medical benefits in young adulthood: The mediating role of upper secondary school completion. *Scandinavian Journal of Public Health*. 2016; 44: 431–438. <https://doi.org/10.1177/1403494815622309>.
- [6] Cui L, Li S, Wang S, Wu X, Liu Y, Yu W, *et al.* Major depressive disorder: hypothesis, mechanism, prevention and treatment. *Signal Transduction and Targeted Therapy*. 2024; 9: 30. <https://doi.org/10.1038/s41392-024-01738-y>.
- [7] Ormel J, Hollon SD, Kessler RC, Cuijpers P, Monroe SM. More treatment but no less depression: The treatment-prevalence paradox. *Clinical Psychology Review*. 2022; 91: 102111. <https://doi.org/10.1016/j.cpr.2021.102111>.
- [8] American Psychiatric Association. APA Clinical practice guideline for the treatment of depression across three age cohorts. Guideline development panel for the treatment of depressive disorders. 2019. Available at: <https://www.apa.org/depression-guideline/guideline.pdf> (Accessed: 15 September 2022).
- [9] Masi G. Controversies in the Pharmacotherapy of Adolescent Depression. *Current Pharmaceutical Design*. 2022; 28: 1975–1984. <https://doi.org/10.2174/1381612828666220526150153>.
- [10] Cuijpers P, Karyotaki E, Ciharova M, Miguel C, Noma H, Stikkelbroek Y, *et al.* The effects of psychological treatments of depression in children and adolescents on response, reliable change, and deterioration: a systematic review and meta-analysis. *European Child & Adolescent Psychiatry*. 2023; 32: 177–192. <https://doi.org/10.1007/s00787-021-01884-6>.
- [11] Qaseem A, Owens DK, Etzeandia-Ikoblantzeta I, Tufte J, Cross JT, Jr, Wilt TJ, *et al.* Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians. *Annals of Internal Medicine*. 2023; 176: 239–252. <https://doi.org/10.7326/M22-2056>.
- [12] Smith CA, Armour M, Lee MS, Wang LQ, Hay PJ. Acupuncture for depression. *The Cochrane Database of Systematic Reviews*. 2018; 3: CD004046. <https://doi.org/10.1002/14651858.CD004046.pub4>.
- [13] Xu G, Xiao Q, Huang B, Lei H, Yin Z, Huang L, *et al.* Clinical Evidence for Association of Acupuncture with Improved Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Control Trials. *Neuropsychobiology*. 2023; 82: 1–13. <https://doi.org/10.1159/000527903>.
- [14] Zhao B, Li Z, Wang Y, Ma X, Wang X, Wang X, *et al.* Manual or electroacupuncture as an add-on therapy to SSRIs for depression: A randomized controlled trial. *Journal of Psychiatric Research*. 2019; 114: 24–33. <https://doi.org/10.1016/j.jpsychires.2019.04.005>.
- [15] Liu Y, Feng H, Mo Y, Gao J, Mao H, Song M, *et al.* Effect of soothing-liver and nourishing-heart acupuncture on early selective serotonin reuptake inhibitor treatment onset for depressive disorder and related indicators of neuroimmunology: a randomized controlled clinical trial. *Journal of Traditional Chinese Medicine*. 2015; 35: 507–513. [https://doi.org/10.1016/s0254-6272\(15\)30132-1](https://doi.org/10.1016/s0254-6272(15)30132-1).
- [16] Wang T, Wang L, Tao W, Chen L. Acupuncture combined with an antidepressant for patients with depression in hospital: a pragmatic randomised controlled trial. *Acupuncture in Medicine: Journal of the British Medical Acupuncture Society*. 2014; 32: 308–312. <https://doi.org/10.1136/acupmed-2013-010469>.
- [17] Nixon MK, Cheng M, Cloutier P. An open trial of auricular acupuncture for the treatment of repetitive self-injury in depressed adolescents. *The Canadian Child and Adolescent Psychiatry Review*. 2003; 12: 10–12.
- [18] Chen N, Wu X, Tu M, Xiong S, Jin J, Qu S, *et al.* Optimizing Treatment for Major Depressive Disorder in Adolescents: The Impact of Intradermal Acupuncture - A Randomized Controlled Trial Protocol. *Neuropsychiatric Disease and Treatment*. 2023; 19: 1819–1832. <https://doi.org/10.2147/NDT.S420489>.
- [19] Xiao X, Hou X, Zhang Z, Li Y, Yu X, Wang Y, *et al.* Efficacy and brain mechanism of transcutaneous auricular vagus nerve stimulation for adolescents with mild to moderate depression: Study protocol for a randomized controlled trial. *Pediatric Investigation*. 2020; 4: 109–117. <https://doi.org/10.1002/ped4.12198>.
- [20] Yu YJ, Xie YF, Feng J, Shi YF. Analysis on adolescent de-

pression treated with acupuncture based on the theory of “taking shaoyang as the pivot”. *Zhongguo Zhen Jiu*. 2019; 39: 1353–1356. <https://doi.org/10.13703/j.0255-2930.2019.12.026>. (In Chinese)

- [21] Qi Y, Liu H, Madsen J, Gong P. Integrating Acupuncture and Mindfulness for Depression: Clinical Evidence, Mechanistic Understanding, and a Case Study in Adolescent Treatment. *Archives*. 2025; 8: 7–18. <https://doi.org/10.30560/mhs.v8n2p7>.
- [22] Wu Q, Lin D, Wen X, Wang S, Fisher D, Fu W, *et al*. Acupuncture effects on emotional reactivity of youth with self-reported depressive symptoms. *Psychoradiology*. 2025; 5: kkaf006. <http://doi.org/10.1093/psyrad/kkaf006>.
- [23] Zhao B, Li T, Smith SM, Xiong D, Wang X, Yang Y, *et al*. Common variants contribute to intrinsic human brain functional networks. *Nature Genetics*. 2022; 54: 508–517. <https://doi.org/10.1038/s41588-022-01039-6>.
- [24] Fan L, Li H, Zhuo J, Zhang Y, Wang J, Chen L, *et al*. The Human Brainnetome Atlas: A New Brain Atlas Based on Connectional Architecture. *Cerebral Cortex*. 2016; 26: 3508–3526. <https://doi.org/10.1093/cercor/bhw157>.
- [25] Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. *The American Journal of Psychiatry*. 2002; 159: 663–665. <https://doi.org/10.1176/appi.ajp.159.4.663>.
- [26] Zhao B, Li Z, Shi C, Liu Y, Sun Y, Li B, *et al*. Acupuncture as Add-on Therapy to SSRIs Can Improve Outcomes of Treatment for Anxious Depression: Subgroup Analysis of the AcuSDep Trial. *Neuropsychiatric Disease and Treatment*. 2024; 20: 1049–1064. <https://doi.org/10.2147/NDT.S446034>.
- [27] Yin X, Li W, Liang T, Lu B, Yue H, Li S, *et al*. Effect of Electroacupuncture on Insomnia in Patients With Depression: A Randomized Clinical Trial. *JAMA Network Open*. 2022; 5: e2220563. <https://doi.org/10.1001/jamanetworkopen.2022.20563>.
- [28] Zhao B, Li Z, Wang Y, Ma X, Wang X, Wang X, *et al*. Can acupuncture combined with SSRIs improve clinical symptoms and quality of life in patients with depression? Secondary outcomes of a pragmatic randomized controlled trial. *Complementary Therapies in Medicine*. 2019; 45: 295–302. <https://doi.org/10.1016/j.ctim.2019.03.015>.
- [29] Huang Y, Wang XJ, Wang LL, Lu SF, Zhu BM, Xu LF. Anti-depressive effect of acupuncture on selective serotonin reuptake inhibitors. *Zhongguo Zhong Xi Yi Jie he Za Zhi*. 2013; 33: 1341–1344.
- [30] Liu Y, Zhang YH, Jin M, Liu WJ. Study on clinical effect enhancement of acupuncture for depression with chronic pain treated with SSRI antidepressants. *Chinese Acupuncture & Moxibustion*. 2013; 33: 689–691.
- [31] Xu MM, Guo P, Ma QY, Zhou X, Wei YL, Wang L, *et al*. Can acupuncture enhance therapeutic effectiveness of antidepressants and reduce adverse drug reactions in patients with depression? A systematic review and meta-analysis. *Journal of Integrative Medicine*. 2022; 20: 305–320. <https://doi.org/10.1016/j.joim.2022.05.002>.
- [32] Cheng Z, Su J, Zhang K, Jiang H, Li B. Epigenetic Mechanism of Early Life Stress-Induced Depression: Focus on the Neurotransmitter Systems. *Frontiers in Cell and Developmental Biology*. 2022; 10: 929732. <https://doi.org/10.3389/fcell.2022.929732>.
- [33] Cao LX, Ren L. Effect of the warming kidney for dredging governor channel acupuncture method on related neurotransmitters and the cAMP-RAF1 signal pathway on depression with kidney yang deficiency syndrome model rats. *Journal of Beijing University of Traditional Chinese Medicine*. 2022; 46: 141–148. (In Chinese)
- [34] Tang YS, Ji Q, Cao J, Teng JY, Deng XF, Li J, *et al*. Influence of Music Electro-acupuncture and Pulsed Electro-acupuncture on the Different Encephalic Regions of Monoamine Neurotransmitter Chronic Unpredictable Mild Stress Depression Model Rats. *Journal of Clinical Acupuncture and Moxibustion*. 2014; 30: 52–55. (In Chinese)
- [35] Kim H, Park HJ, Han SM, Hahm DH, Lee HJ, Kim KS, *et al*. The effects of acupuncture stimulation at PC6 (Neiguan) on chronic mild stress-induced biochemical and behavioral responses. *Neuroscience Letters*. 2009; 460: 56–60. <https://doi.org/10.1016/j.neulet.2009.05.008>.
- [36] Aarsland TI, Leskauskaite I, Middtun Ø, Ulvik A, Ueland PM, Oltedal L, *et al*. The effect of electroconvulsive therapy (ECT) on serum tryptophan metabolites. *Brain Stimulation*. 2019; 12: 1135–1142. <https://doi.org/10.1016/j.brs.2019.05.018>.
- [37] Ryan KM, Allers KA, McLoughlin DM, Harkin A. Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy. *Brain, Behavior, and Immunity*. 2020; 83: 153–162. <https://doi.org/10.1016/j.bbi.2019.10.005>.
- [38] Paul ER, Schwieler L, Erhardt S, Boda S, Trepci A, Kämpe R, *et al*. Peripheral and central kynurenine pathway abnormalities in major depression. *Brain, Behavior, and Immunity*. 2022; 101: 136–145. <https://doi.org/10.1016/j.bbi.2022.01.002>.
- [39] Colle R, Masson P, Verstuyft C, Fève B, Werner E, Boursier-Neyret C, *et al*. Peripheral tryptophan, serotonin, kynurenine, and their metabolites in major depression: A case-control study. *Psychiatry and Clinical Neurosciences*. 2020; 74: 112–117. <http://doi.org/10.1111/pcn.12944>.
- [40] Brundin L, Sellgren CM, Lim CK, Grit J, Pålsson E, Landén M, *et al*. An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation. *Translational Psychiatry*. 2016; 6: e865. <https://doi.org/10.1038/tp.2016.133>.
- [41] Zhang C, Zhu GQ, Wang JJ, Li XJ, Li M, Wang XC. Study on the mechanism of acupuncture underlying improvement of functional dyspepsia with depression-like behavior in rats. *Zhen Ci Yan Jiu*. 2025; 50: 76–83. <https://doi.org/10.13702/j.1000-0607.20230948>. (In Chinese)
- [42] Bao C, Huang J, Wu H, Ma Y, Zhou H, Chen L, *et al*. Moxibustion alleviates depression-like behavior in rats with Crohn’s disease by inhibiting the kynurenine pathway metabolism in the gut-brain axis. *Frontiers in Neuroscience*. 2022; 16: 1019590. <https://doi.org/10.3389/fnins.2022.1019590>.
- [43] Wang J, Zhu H, Song X, Zhao J, Zhang J, Zhang J, *et al*. Electroacupuncture regulates gut microbiota to reduce depressive-like behavior in rats. *Frontiers in Microbiology*. 2024; 15: 1327630. <https://doi.org/10.3389/fmicb.2024.1327630>.
- [44] Wu X, Hu R, Jiang S, Di Z, Chen Y, Shi M, *et al*. Electroacupuncture attenuates LPS-induced depression-like behavior through kynurenine pathway. *Frontiers in Behavioral Neuroscience*. 2023; 16: 1052032. <https://doi.org/10.3389/fnbeh.2022.1052032>.
- [45] Solís-Ortiz S, Arriaga-Avila V, Trejo-Bahena A, Guevara-Guzmán R. Deficiency in the Essential Amino Acids L-Isoleucine, L-Leucine and L-Histidine and Clinical Measures as Predictors of Moderate Depression in Elderly Women: A Discriminant Analysis Study. *Nutrients*. 2021; 13: 3875. <https://doi.org/10.3390/nu13113875>.
- [46] Qian H, Shu C, Xiao L, Wang G. Histamine and histamine receptors: Roles in major depressive disorder. *Frontiers in Psychiatry*. 2022; 13: 825591. <https://doi.org/10.3389/fpsy.2022.825591>.
- [47] Liu CH, Zhang GZ, Li B, Li M, Woelfer M, Walter M, *et al*. Role of inflammation in depression relapse. *Journal of Neuroinflammation*. 2019; 16: 90. <https://doi.org/10.1186/s12974-019-1475-7>.
- [48] Qiu H, Li X, Luo Q, Li Y, Zhou X, Cao H, *et al*. Alterations in patients with major depressive disorder before and after elec-



- troconvulsive therapy measured by fractional amplitude of low-frequency fluctuations (fALFF). *Journal of Affective Disorders*. 2019; 244: 92–99. <https://doi.org/10.1016/j.jad.2018.10.099>.
- [49] Yi Y, Xu FM, Xie P, Lv FJ, Li Y, Wu Y, *et al.* Acupuncture Taichong point for regulating the brain function of depression patients: resting-state fMRI study. *China Journal of Traditional Chinese Medicine and Pharmacy*. 2012; 27: 369–373. (In Chinese)
- [50] Yang H. Clinical Basic Research on Mechanism of Acupuncture Treatment for geriatric depression Based on Magnetic Resonance Imaging Technology [Master's thesis]. Chengdu University of Traditional Chinese Medicine: Chengdu, China. 2018.
- [51] Yi Y, Xu FM, Xie HW. Correlation between the liver meridian and the frontal lobe in depression by needling at taichong (LV3): a resting-state fMRI study. *Chinese Journal of Integrated Traditional and Western Medicine*. 2011; 31: 1044–1050. (In Chinese)
- [52] Fonseka TM, MacQueen GM, Kennedy SH. Neuroimaging biomarkers as predictors of treatment outcome in Major Depressive Disorder. *Journal of Affective Disorders*. 2018; 233: 21–35. <https://doi.org/10.1016/j.jad.2017.10.049>.
- [53] Greicius MD, Flores BH, Menon V, Glover GH, Solvason HB, Kenna H, *et al.* Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. *Biological Psychiatry*. 2007; 62: 429–437. <https://doi.org/10.1016/j.biopsych.2006.09.020>.
- [54] Whitfield-Gabrieli S, Ford JM. Default mode network activity and connectivity in psychopathology. *Annual Review of Clinical Psychology*. 2012; 8: 49–76. <https://doi.org/10.1146/annurev-clinpsy-032511-143049>.
- [55] Mulders PC, van Eijndhoven PF, Schene AH, Beckmann CF, Tendolkar I. Resting-state functional connectivity in major depressive disorder: A review. *Neuroscience and Biobehavioral Reviews*. 2015; 56: 330–344. <https://doi.org/10.1016/j.neubiorev.2015.07.014>.
- [56] Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA. Large-Scale Network Dysfunction in Major Depressive Disorder: A Meta-analysis of Resting-State Functional Connectivity. *JAMA Psychiatry*. 2015; 72: 603–611. <https://doi.org/10.1001/jamapsychiatry.2015.0071>.
- [57] Korgaonkar MS, Goldstein-Piekarski AN, Fornito A, Williams LM. Intrinsic connectomes are a predictive biomarker of remission in major depressive disorder. *Molecular Psychiatry*. 2020; 25: 1537–1549. <https://doi.org/10.1038/s41380-019-0574-2>.
- [58] Zhang S, Chen JM, Kuang L, Cao J, Zhang H, Ai M, *et al.* Association between abnormal default mode network activity and suicidality in depressed adolescents. *BMC Psychiatry*. 2016; 16: 337. <https://doi.org/10.1186/s12888-016-1047-7>.
- [59] Kerestes R, Davey CG, Stephanou K, Whittle S, Harrison BJ. Functional brain imaging studies of youth depression: a systematic review. *NeuroImage. Clinical*. 2013; 4: 209–231. <https://doi.org/10.1016/j.nicl.2013.11.009>.
- [60] Liston C, Chen AC, Zebly BD, Drysdale AT, Gordon R, Leuchter B, *et al.* Default mode network mechanisms of transcranial magnetic stimulation in depression. *Biological Psychiatry*. 2014; 76: 517–526. <https://doi.org/10.1016/j.biopsych.2014.01.023>.
- [61] Deng D, Liao H, Duan G, Liu Y, He Q, Liu H, *et al.* Modulation of the Default Mode Network in First-Episode, Drug-Naïve Major Depressive Disorder via Acupuncture at Baihui (GV20) Acupoint. *Frontiers in Human Neuroscience*. 2016; 10: 230. <https://doi.org/10.3389/fnhum.2016.00230>.
- [62] Wei XY, Chen H, Guo C, Tan WL, Zhan SH. The Instant and Sustained Effect of Electroacupuncture in Postgraduate Students with Depression: An fMRI Study. *Neuropsychiatric Disease and Treatment*. 2021; 17: 873–883. <https://doi.org/10.2147/NDT.S307083>.
- [63] Clark L, Chamberlain SR, Sahakian BJ. Neurocognitive mechanisms in depression: implications for treatment. *Annual Review of Neuroscience*. 2009; 32: 57–74. <https://doi.org/10.1146/annurev-neuro.31.060407.125618>.
- [64] Rive MM, van Rooijen G, Veltman DJ, Phillips ML, Schene AH, Ruhé HG. Neural correlates of dysfunctional emotion regulation in major depressive disorder. A systematic review of neuroimaging studies. *Neuroscience and Biobehavioral Reviews*. 2013; 37: 2529–2553. <https://doi.org/10.1016/j.neubiorev.2013.07.018>.
- [65] Guo H, Cheng C, Cao X, Xiang J, Chen J, Zhang K. Resting-state functional connectivity abnormalities in first-onset unmedicated depression. *Neural Regeneration Research*. 2014; 9: 153–163. <https://doi.org/10.4103/1673-5374.125344>.
- [66] Drevets WC. Neuroimaging studies of mood disorders. *Biological Psychiatry*. 2000; 48: 813–829. [https://doi.org/10.1016/s0006-3223\(00\)01020-9](https://doi.org/10.1016/s0006-3223(00)01020-9).
- [67] Knight G. Stereotactic tractotomy in the surgical treatment of mental illness. *Journal of Neurology, Neurosurgery, and Psychiatry*. 1965; 28: 304–310. <https://doi.org/10.1136/jnnp.28.4.304>.
- [68] Newcombe R. The lesion in stereotactic suscaudate tractotomy. *The British Journal of Psychiatry: the Journal of Mental Science*. 1975; 126: 478–481. <https://doi.org/10.1192/bjp.126.5.478>.
- [69] Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. *Progress in Neuro-psychopharmacology & Biological Psychiatry*. 2013; 45: 54–63. <https://doi.org/10.1016/j.pnpbp.2013.04.009>.
- [70] Wade BSC, Joshi SH, Njau S, Leaver AM, Vasavada M, Woods RP, *et al.* Effect of Electroconvulsive Therapy on Striatal Morphometry in Major Depressive Disorder. *Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology*. 2016; 41: 2481–2491. <https://doi.org/10.1038/npp.2016.48>.
- [71] Segawa K, Azuma H, Sato K, Yasuda T, Arahata K, Otsuki K, *et al.* Regional cerebral blood flow changes in depression after electroconvulsive therapy. *Psychiatry Research*. 2006; 147: 135–143. <https://doi.org/10.1016/j.psychresns.2004.08.006>.
- [72] Li Y. Central Mechanism involved in Acupuncture Depression basedon fMRI Study [Master's thesis]. Chengdu University of Traditional Chinese Medicine: Chengdu, China. 2014.
- [73] Wang Z, He JK, Sun JF, Chen LM, Guo CL, Zhang GL, *et al.* Instant brain effect of transcuteaneous auricular vagus nerve stimulation in treating the treatment-resistant depression by resting rtate functional magnetic resonance imaging. *Chinese Journal of Magnetic Resonance Imaging*. 2022; 13: 70–75+97. [https://www.med-sci.cn/cgzcx/articlexml\\_en.asp?doi=10.12015/issn.1674-8034.2022.01.014&html](https://www.med-sci.cn/cgzcx/articlexml_en.asp?doi=10.12015/issn.1674-8034.2022.01.014&html). (In Chinese)
- [74] Drevets WC. Neuroplasticity in mood disorders. *Dialogues in Clinical Neuroscience*. 2004; 6: 199–216. <https://doi.org/10.31887/DCNS.2004.6.2/wdrevets>.
- [75] Chen YH, Dammers J, Boers F, Leiberg S, Edgar JC, Roberts TPL, *et al.* The temporal dynamics of insula activity to disgust and happy facial expressions: a magnetoencephalography study. *NeuroImage*. 2009; 47: 1921–1928. <https://doi.org/10.1016/j.neuroimage.2009.04.093>.
- [76] Pan P, Wang L, Wu C, Jin K, Cao S, Qiu Y, *et al.* Global Functional Connectivity Analysis Indicating Dysconnectivity of the Hate Circuit in Major Depressive Disorder. *Frontiers in Aging Neuroscience*. 2022; 13: 803080. <https://doi.org/10.3389/fnagi.2021.803080>.
- [77] Tao H, Guo S, Ge T, Kendrick KM, Xue Z, Liu Z, *et al.* Depression uncouples brain hate circuit. *Molecular Psychiatry*. 2013; 18: 101–111. <https://doi.org/10.1038/mp.2011.127>.
- [78] Kandilarova S, Stoyanov D, Kostianev S, Specht K. Altered Resting State Effective Connectivity of Anterior Insula in De-



- pression. *Frontiers in Psychiatry*. 2018; 9: 83. <https://doi.org/10.3389/fpsyt.2018.00083>.
- [79] Hwang JW, Egorova N, Yang XQ, Zhang WY, Chen J, Yang XY, *et al*. Subthreshold depression is associated with impaired resting-state functional connectivity of the cognitive control network. *Translational Psychiatry*. 2015; 5: e683. <https://doi.org/10.1038/tp.2015.174>.
- [80] Fan Z, Yang J, Zeng C, Xi C, Wu G, Guo S, *et al*. Bipolar Mood State Reflected in Functional Connectivity of the Hate Circuit: A Resting-State Functional Magnetic Resonance Imaging Study. *Frontiers in Psychiatry*. 2020; 11: 556126. <https://doi.org/10.3389/fpsyt.2020.556126>.
- [81] Wang L, Li F, Mitchell PB, Wang CY, Si TM. Striatal Resting-State Connectivity Abnormalities Associated With Different Clinical Stages of Major Depressive Disorder. *The Journal of Clinical Psychiatry*. 2020; 81: 19m12790. <https://doi.org/10.4088/JCP.19m12790>.